Financial Ratios Clinitech Laboratory Limited
Stocks
544220
INE0QMR01015
Healthcare Facilities & Services
|
Market Closed -
Bombay S.E.
13:02:28 07/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 32.00 INR | -4.90% |
|
-8.83% | -23.99% |
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) | 2026 (INR) |
|---|---|---|---|---|---|---|
Profitability | ||||||
Return on Assets | 13.39 | 11.65 | 5.95 | 2.93 | 2.88 | |
Return on Total Capital | 18.44 | 18.43 | 8.86 | 3.61 | 3.41 | |
Return On Equity % | 31.66 | 29 | 12.52 | 6.38 | 4.59 | |
Return on Common Equity | 31.66 | 29 | 12.52 | 6.38 | 4.62 | |
Margin Analysis | ||||||
Gross Profit Margin % | 71.52 | 77.72 | 78.47 | 77.15 | 72.29 | |
SG&A Margin | 27.86 | 32.01 | 35.73 | 35.5 | 37.83 | |
EBITDA Margin % | 16.74 | 21.3 | 15.51 | 10.1 | 10.7 | |
EBITA Margin % | 10.78 | 14.32 | 8.74 | 4.64 | 5.35 | |
EBIT Margin % | 10.77 | 14.27 | 8.66 | 4.64 | 5.35 | |
Income From Continuing Operations Margin % | 8.03 | 9.66 | 5.8 | 4.79 | 4.37 | |
Net Income Margin % | 8.03 | 9.66 | 5.8 | 4.79 | 4.4 | |
Net Avail. For Common Margin % | 8.03 | 9.66 | 5.8 | 4.79 | 4.4 | |
Normalized Net Income Margin | 6.88 | 8.5 | 4.83 | 3.69 | 3.96 | |
Levered Free Cash Flow Margin | -9.02 | 15.32 | -20.36 | -25.21 | -16.49 | |
Unlevered Free Cash Flow Margin | -8.61 | 15.89 | -19.64 | -24.88 | -16.28 | |
Asset Turnover | ||||||
Asset Turnover | 1.99 | 1.31 | 1.1 | 1.01 | 0.86 | |
Fixed Assets Turnover | 4.29 | 3.23 | 2.83 | 4.3 | 4.2 | |
Receivables Turnover (Average Receivables) | 13.84 | 14.88 | 11.78 | 7.7 | 5.59 | |
Inventory Turnover (Average Inventory) | 14.84 | 9.52 | 6.48 | 4.63 | 4.18 | |
Short Term Liquidity | ||||||
Current Ratio | 1.02 | 1.12 | 1.66 | 4.36 | 6.5 | |
Quick Ratio | 0.34 | 0.72 | 0.8 | 2.77 | 3.5 | |
Operating Cash Flow to Current Liabilities | 0.7 | 0.71 | 0.07 | -0.52 | -0.7 | |
Days Sales Outstanding (Average Receivables) | 26.37 | 24.53 | 31.07 | 47.42 | 65.29 | |
Days Outstanding Inventory (Average Inventory) | 24.59 | 38.35 | 56.48 | 78.85 | 87.37 | |
Average Days Payable Outstanding | 94.73 | 119.71 | 89.7 | 83.6 | 79.82 | |
Cash Conversion Cycle (Average Days) | -43.77 | -56.83 | -2.15 | 42.67 | 72.85 | |
Long Term Solvency | ||||||
Total Debt/Equity | 47.95 | 43.22 | 24.33 | - | 5.81 | |
Total Debt / Total Capital | 32.41 | 30.18 | 19.57 | - | 5.49 | |
LT Debt/Equity | 19.32 | 11.85 | 6.59 | - | 5.81 | |
Long-Term Debt / Total Capital | 13.06 | 8.27 | 5.3 | - | 5.49 | |
Total Liabilities / Total Assets | 49.88 | 60.54 | 36.73 | 17.57 | 17.22 | |
EBIT / Interest Expense | 16.53 | 15.57 | 7.55 | 8.91 | 15.63 | |
EBITDA / Interest Expense | 25.69 | 23.23 | 13.53 | 19.39 | 31.26 | |
(EBITDA - Capex) / Interest Expense | -10.7 | 18.42 | -2.9 | -7.76 | 5.85 | |
Total Debt / EBITDA | 0.83 | 0.76 | 0.87 | - | 0.53 | |
Net Debt / EBITDA | 0.73 | 0.18 | 0.16 | -3.7 | -1.55 | |
Total Debt / (EBITDA - Capex) | -1.99 | 0.96 | -4.05 | - | 2.83 | |
Net Debt / (EBITDA - Capex) | -1.76 | 0.23 | -0.76 | 9.24 | -8.28 | |
Growth Over Prior Year | ||||||
Total Revenues, 1 Yr. Growth % | 40.19 | -0.58 | 0.87 | 28.61 | 15.26 | |
Gross Profit, 1 Yr. Growth % | 40.73 | 8.04 | 1.85 | 26.45 | 7.99 | |
EBITDA, 1 Yr. Growth % | 29.65 | 26.5 | -26.51 | -16.39 | 18.22 | |
EBITA, 1 Yr. Growth % | 18.6 | 32.14 | -38.41 | -31.95 | 23.25 | |
EBIT, 1 Yr. Growth % | 18.81 | 31.72 | -38.81 | -31.95 | 23.25 | |
Earnings From Cont. Operations, 1 Yr. Growth % | 27.39 | 19.61 | -39.46 | 6.33 | 5.09 | |
Net Income, 1 Yr. Growth % | 27.39 | 19.61 | -39.46 | 6.33 | 5.88 | |
Normalized Net Income, 1 Yr. Growth % | 36.24 | 22.98 | -42.75 | -1.6 | 23.5 | |
Diluted EPS Before Extra, 1 Yr. Growth % | 27.39 | 19.61 | -42.03 | -19.98 | -3.49 | |
Accounts Receivable, 1 Yr. Growth % | -34.75 | 34.2 | 22.38 | 157.63 | 20.36 | |
Inventory, 1 Yr. Growth % | 74.97 | -9.36 | 101.06 | 86.1 | 38.17 | |
Net Property, Plant and Equip., 1 Yr. Growth % | 123.16 | -8.35 | 40.87 | 24.15 | 13.18 | |
Total Assets, 1 Yr. Growth % | 34.91 | 63.62 | -7.05 | 91.02 | 3.12 | |
Tangible Book Value, 1 Yr. Growth % | 32.99 | 28.6 | 49.25 | 200.8 | 5.14 | |
Common Equity, 1 Yr. Growth % | 32.93 | 28.82 | 49.03 | 148.87 | 4.73 | |
Cash From Operations, 1 Yr. Growth % | 154.04 | 30.53 | -90.98 | -31.43 | -9.8 | |
Capital Expenditures, 1 Yr. Growth % | 700.9 | -81.52 | 331.36 | -3.47 | -29.09 | |
Levered Free Cash Flow, 1 Yr. Growth % | - | -268.91 | -234.04 | 59.84 | -23.89 | |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | -283.52 | -224.66 | 63.47 | -23.89 | |
Compound Annual Growth Rate Over Two Years | ||||||
Total Revenues, 2 Yr. CAGR % | - | 18.06 | 0.15 | 13.9 | 21.75 | |
Gross Profit, 2 Yr. CAGR % | - | 23.31 | 4.9 | 13.49 | 16.85 | |
EBITDA, 2 Yr. CAGR % | - | 28.07 | -3.58 | -21.55 | 1.05 | |
EBITA, 2 Yr. CAGR % | - | 25.19 | -9.79 | -35.17 | -4.89 | |
EBIT, 2 Yr. CAGR % | - | 25.1 | -10.22 | -35.06 | -4.89 | |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 23.43 | -14.9 | -19.76 | 5.71 | |
Net Income, 2 Yr. CAGR % | - | 23.43 | -14.9 | -19.76 | 6.1 | |
Normalized Net Income, 2 Yr. CAGR % | - | 29.44 | -16.09 | -24.94 | 10.25 | |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | 23.43 | -16.73 | -31.89 | -12.12 | |
Accounts Receivable, 2 Yr. CAGR % | - | -6.42 | 28.15 | 77.56 | 76.07 | |
Inventory, 2 Yr. CAGR % | - | 25.93 | 34.99 | 93.43 | 60.35 | |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | 43.01 | 13.62 | 6.13 | 18.54 | |
Total Assets, 2 Yr. CAGR % | - | 48.57 | 23.32 | 33.25 | 41.19 | |
Tangible Book Value, 2 Yr. CAGR % | - | 30.78 | 38.54 | 81.48 | 77.84 | |
Common Equity, 2 Yr. CAGR % | - | 30.86 | 38.56 | 92.59 | 61.45 | |
Cash From Operations, 2 Yr. CAGR % | - | 82.1 | -65.7 | -16.06 | -21.35 | |
Capital Expenditures, 2 Yr. CAGR % | - | 21.65 | -10.72 | 104.05 | -17.27 | |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | 50.47 | 46.1 | 9.8 | |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | 51.25 | 42.51 | 11.03 | |
Compound Annual Growth Rate Over Three Years | ||||||
Total Revenues, 3 Yr. CAGR % | - | - | 12.03 | 8.86 | 14.35 | |
Gross Profit, 3 Yr. CAGR % | - | - | 15.7 | 11.64 | 11.62 | |
EBITDA, 3 Yr. CAGR % | - | - | 6.42 | -8.01 | -9.08 | |
EBITA, 3 Yr. CAGR % | - | - | -1.17 | -17.8 | -17.64 | |
EBIT, 3 Yr. CAGR % | - | - | -1.43 | -17.79 | -17.55 | |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | -2.65 | -8.34 | -12.21 | |
Net Income, 3 Yr. CAGR % | - | - | -2.65 | -8.34 | -11.99 | |
Normalized Net Income, 3 Yr. CAGR % | - | - | -1.38 | -11.51 | -11.38 | |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | -4.05 | -17.83 | -23.5 | |
Accounts Receivable, 3 Yr. CAGR % | - | - | 2.33 | 61.74 | 55.96 | |
Inventory, 3 Yr. CAGR % | - | - | 47.19 | 50.24 | 72.91 | |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | 42.29 | 1.06 | 8.43 | |
Total Assets, 3 Yr. CAGR % | - | - | 27.07 | 42.69 | 22.82 | |
Tangible Book Value, 3 Yr. CAGR % | - | - | 36.66 | 61.79 | 51.29 | |
Common Equity, 3 Yr. CAGR % | - | - | 36.65 | 68.43 | 57.2 | |
Cash From Operations, 3 Yr. CAGR % | - | - | -33.13 | -2.77 | -14.02 | |
Capital Expenditures, 3 Yr. CAGR % | - | - | 85.5 | -8.37 | 43.46 | |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 53.34 | 17.2 | |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 55.04 | 15.27 | |
Compound Annual Growth Rate Over Five Years | ||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | - | 15.82 | |
Gross Profit, 5 Yr. CAGR % | - | - | - | - | 16.16 | |
EBITDA, 5 Yr. CAGR % | - | - | - | - | 4.27 | |
EBITA, 5 Yr. CAGR % | - | - | - | - | -2.62 | |
EBIT, 5 Yr. CAGR % | - | - | - | - | -2.58 | |
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | - | 0.61 | |
Net Income, 5 Yr. CAGR % | - | - | - | - | 0.76 | |
Normalized Net Income, 5 Yr. CAGR % | - | - | - | - | 3.12 | |
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | - | -7.36 | |
Accounts Receivable, 5 Yr. CAGR % | - | - | - | - | 27.14 | |
Inventory, 5 Yr. CAGR % | - | - | - | - | 52.32 | |
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | - | 21.13 | |
Total Assets, 5 Yr. CAGR % | - | - | - | - | 32.54 | |
Tangible Book Value, 5 Yr. CAGR % | - | - | - | - | 42.72 | |
Common Equity, 5 Yr. CAGR % | - | - | - | - | 46.08 | |
Cash From Operations, 5 Yr. CAGR % | - | - | - | - | 16.07 | |
Capital Expenditures, 5 Yr. CAGR % | - | - | - | - | 34.3 |
- Stock Market
- Stocks
- 544220 Stock
- Financials Clinitech Laboratory Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















